ArticleNature2024
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
23.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 92 citations in OpenAlex.
- Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331.Pediatric blood & cancer · 2025Trial
- High-quantity capture of heterogeneous circulating tumor cellsMaterials today. Bio · 2026Article
- Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.Blood advances · 2026Review
- [Diagnosis of classic Hodgkin lymphoma and its imitators].Pathologie (Heidelberg, Germany) · 2026Review
- Hierarchical vision transformers for Epstein-Barr virus status and histological subtype prediction in Hodgkin lymphoma whole-slide images.Journal of pathology informatics · 2026Article
- To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma.Haematologica · 2026Article
- Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.Cancer · 2026Article
- Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma.Blood cancer journal · 2026Article
- Systemic Therapy for Advanced-Stage Hodgkin Lymphoma.Cancers · 2026Review
- Review
- Epidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases.International journal of cancer · 2026Article
- Article
- Predictors of sensitivity to immune therapies in classic Hodgkin lymphoma.Blood neoplasia · 2026Review
- Hodgkin Reed-Sternberg Cells of Classic Hodgkin Lymphoma: Morphology, Phenotype, Genotype, and Cell of Origin.Cancers · 2026Review
- Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.Blood cancer journal · 2026Article
- The Hodgkin Lymphoma Microenvironment: Insights from Spatial Transcriptomics.International journal of molecular sciences · 2026Review
- Integration of circulating tumor DNA profiling in the risk stratification of classical Hodgkin lymphoma in children, adolescents, and young adults.HemaSphere · 2026Article
- Rapid molecular response kinetics to anti-PD-1-based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.Blood advances · 2026Article
- The CCL17-CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.Cancer immunology research · 2026Article
- Integrating liquid biopsy and mutational signatures to advance precision oncology.NPJ precision oncology · 2026Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors at 12 institutions in 5 countries.
Stefan K Alig *Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.ORCID 0000-0001-6825-702X
Mohammad Shahrokh Esfahani *Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Andrea Garofalo *Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Michael Yu Li *Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
Cédric RossiDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Tim FlerlageDepartment of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA.
Jamie E FlerlageDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
Ragini AdamsDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Stanford University, Stanford, CA, USA.
Michael S BinkleyDepartment of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA.
Navika ShuklaDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Michael C JinDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Mari OlsenDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Adèle TeleniusCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
Jurik A MutterDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Joseph G Schroers-MartinDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.ORCID 0000-0003-4128-2537
Brian J SworderDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Shinya RaiCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
Daniel A KingDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.ORCID 0000-0001-6451-712X
Andre SchultzDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Jan BögeholzDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-7196-1621
Shengqin SuDepartment of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA.ORCID 0000-0002-6946-8256
Karan R KathuriaDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Chih Long LiuDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-6577-5427
Xiaoman KangDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Maya J StrohbandDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Deanna LangfittDepartment of Bone Marrow Transplant and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-0941-5360
Kristine Faye Pobre-PizaDepartment of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA.
Sherri SurmanDepartment of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA.
Feng TianDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-2657-5158
Valeria SpinaLaboratory of Molecular Diagnostics, Department of Medical Genetics EOLAB, Bellinzona, Switzerland.
Thomas TousseynDepartment of Imaging and Pathology, KU Leuven, Leuven, Belgium.ORCID 0000-0002-0397-1086
Lieselot BuedtsDepartment of Human Genetics, KU Leuven, Leuven, Belgium.
Richard HoppeDepartment of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA.ORCID 0000-0003-0125-0194
Yasodha NatkunamDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-9816-1018
Luc-Matthieu ForneckerInstitut de Cancérologie Strasbourg Europe (ICANS) and University of Strasbourg, Strasbourg, France.
Sharon M CastellinoDepartment of Pediatrics, Emory University, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Ranjana AdvaniDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.
Davide RossiClinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Ryan LynchClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Hervé GhesquièresDepartment of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France.
Olivier CasasnovasHematology Department, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France.
David M KurtzDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-6382-4651
Lianna J MarksDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Stanford University, Stanford, CA, USA.
Michael P LinkDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Stanford University, Stanford, CA, USA.
Marc AndréDepartment of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
Peter VandenbergheDepartment of Human Genetics, KU Leuven, Leuven, Belgium.ORCID 0000-0003-4719-1935
Christian SteidlCentre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.ORCID 0000-0001-9842-9750
Maximilian DiehnDepartment of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA. diehn@stanford.edu.ORCID 0000-0003-2032-0581
Ash A AlizadehDepartment of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA, USA. arasha@stanford.edu.ORCID 0000-0002-5153-5625
Stanford University · USStanford Medicine · USSt. Jude Children's Research Hospital · USSpinal Cord Injury BC · CAKU Leuven · BEInserm · FREmory University · USEnte Ospedaliero Cantonale · CHFred Hutch Cancer Center · USHospices Civils de Lyon · FRInstitut de Cancérologie Strasbourg · FRUCLouvain · BE
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MCOG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in ChildrenUG1CA233249 · NCI · PUBLIC HEALTH INSTITUTE · PI MESHINCHI, SOHEIL · 2019 to 2025
$4.9MCirculating Genomic Determinants of Treatment Failure in Hodgkin LymphomaR01CA257655 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2021 to 2025
$3.2MAnalysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerR01CA244526 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.0MA Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma TherapyR01CA233975 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2019 to 2023
$2.8MMolecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNAK08CA241076 · NCI · STANFORD UNIVERSITY · PI KURTZ, DAVID MATTHEW · 2019 to 2023
$957kNCI NIH HHS K08 CA241076NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA233975NCI NIH HHS R01 CA244526NCI NIH HHS R01 CA257655NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS UG1 CA233249
Abstract
The scarcity of malignant Hodgkin and Reed-Sternberg cells hampers tissue-based comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid biopsies show promise for molecular profiling of cHL due to relatively high circulating tumour DNA (ctDNA) levels
Indexed as
Circulating Tumor DNAGenome, HumanGenomicsHodgkin DiseaseEndodeoxyribonucleasesHumansInterleukin-13Interleukin-4 Receptor alpha SubunitMutationReed-Sternberg CellsSingle-Cell Gene Expression AnalysisTumor MicroenvironmentCirculating Tumor DNADNASE1L3 protein, humanEndodeoxyribonucleasesIL13 protein, humanIL4R protein, humanInterleukin-13Interleukin-4 Receptor alpha Subunit
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.